In the initial NORDIC NEC trial, patients with Ki67 ≥ 55% had a poorer mOS of 11 months compared to 14 months in patients with Ki67 < 55%, but the proliferation rate was not a statistically independent prognostic parameter in multivariate analysis [16]. The gene discussed is MKI67; the disease is neuroendocrine carcinoma.